Pioglitazone prevents the endothelial dysfunction induced by ischemia and reperfusion in healthy subjects

Journal of Cardiovascular Pharmacology

Volumn 64, Issue 4, 2014, Pages 326-331

  Sakatani, Yuka ^a   Miyoshi, Toru ^b   Oe, Hiroki ^c   Noda, Yoko ^a   Ohno, Yuko ^a   Nakamura, Kazufumi ^a   Saito, Yukihiro ^a   Osawa, Kazuhiro ^a   Morita, Hiroshi ^a   Kohno, Kunihisa ^a   Ito, Hiroshi ^a  

^a Departments of Medicine   (United States)

^b OKAYAMA UNIVERSITY   (Japan)

^c OKAYAMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Brachial artery; Cyclooxygenase 2 pathway; Endothelium; Flow mediated dilation; Ischemia and reperfusion; Pioglitazone

Indexed keywords

EXTRACELLULAR SUPEROXIDE DISMUTASE; MELOXICAM; PIOGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SUPEROXIDE DISMUTASE; THIAZINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADULT; ARTERY DIAMETER; ARTICLE; BLOOD SAMPLING; BRACHIAL ARTERY; CARDIOVASCULAR FUNCTION; CONTROLLED STUDY; CROSSOVER PROCEDURE; ENDOTHELIAL DYSFUNCTION; ENZYME BLOOD LEVEL; FEMALE; FLOW MEDIATED DILATION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPERFUSION INJURY; AGONISTS; BLOOD; BLOOD FLOW VELOCITY; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; PATHOPHYSIOLOGY; VASCULAR ENDOTHELIUM; VASODILATATION;

ADULT; BLOOD FLOW VELOCITY; BRACHIAL ARTERY; CROSS-OVER STUDIES; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; ENDOTHELIUM, VASCULAR; FEMALE; HEALTHY VOLUNTEERS; HUMANS; MALE; PPAR GAMMA; REPERFUSION INJURY; SUPEROXIDE DISMUTASE; THIAZINES; THIAZOLES; THIAZOLIDINEDIONES; VASODILATION;

EID: 84928104099     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000124     Document Type: Article

References (38)

1. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127:529-555.
2. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007;357:1121-1135.
3. Kharbanda RK, Peters M, Walton B, et al. Ischemic preconditioning prevents endothelial injury and systemic neutrophil activation during ischemia-reperfusion in humans in vivo. Circulation. 2001;103:1624- 1630.
4. Mankad PS, Amrani M, Rothery S, et al. Relative susceptibility of endothelium and myocardial cells to ischaemia-reperfusion injury. Acta Physiol Scand. 1997;161:103-112.
5. Laude K, Beauchamp P, Thuillez C, et al. Endothelial protective effects of preconditioning. Cardiovasc Res. 2002;55:466-473.
6. Wayman NS, Hattori Y, McDonald MC, et al. Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J. 2002;16:1027-1040.
7. Liuni A, Luca MC, Gori T, et al. Rosuvastatin prevents conduit artery endothelial dysfunction induced by ischemia and reperfusion by a cyclooxygenase- 2-dependent mechanism. J Am Coll Cardiol. 2010;55:1002- 1006.
8. Gori T, Sicuro S, Dragoni S, et al. Sildenafil prevents endothelial dysfunction induced by ischemia and reperfusion via opening of adenosine triphosphate-sensitive potassium channels: A human in vivo study. Circulation. 2005;111:742-746.
9. Dragoni S, Gori T, Lisi M, et al. Pentaerythrityl tetranitrate and nitroglycerin, but not isosorbide mononitrate, prevent endothelial dysfunction induced by ischemia and reperfusion. Arterioscler Thromb Vasc Biol. 2007;27:1955-1959.
10. Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature. 2000;405:421-424.
11. Ito H, Nakano A, Kinoshita M, et al. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia/reperfusion injury in a rat model. Lab Invest. 2003;83:1715- 1721.
12. Ye Y, Perez-Polo JR, Aguilar D, et al. The potential effects of antidiabetic medications on myocardial ischemia-reperfusion injury. Basic Res Cardiol. 2011;106:925-952.
13. Kataoka Y, Yagi N, Kokubu N, et al. Effect of pretreatment with pioglitazone on reperfusion injury in diabetic patients with acute myocardial infarction. Circ J. 2011;75:1968-1974.
14. Noda Y, Miyoshi T, Oe H, et al. Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non-diabetic subjects: A preliminary report. Cardiovasc Diabetol. 2013;12:8.
15. Ha SJ, Kim W, Woo JS, et al. Preventive effects of exenatide on endothelial dysfunction induced by ischemia-reperfusion injury via KATP channels. Arterioscler Thromb Vasc Biol. 2012;32:474-480.
16. Ohno Y, Miyoshi T, Noda Y, et al. Bezafibrate improves postprandial hypertriglyceridemia and associated endothelial dysfunction in patients with metabolic syndrome: A randomized crossover study. Cardiovasc Diabetol. 2014;13:71.
17. Cao Z, Ye P, Long C, et al. Effect of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on ischemia-reperfusion injury in rats. Pharmacology. 2007;79:184-192.
18. Birnbaum Y, Long B, Qian J, et al. Pioglitazone limits myocardial infarct size, activates Akt, and upregulates cPLA2 and COX-2 in a PPARgamma- independent manner. Basic Res Cardiol. 2011;106:431-446.
19. Shiomi T, Tsutsui H, Hayashidani S, et al. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation. 2002;106:3126-3132.
20. Gryglewski RJ, Palmer RM, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature. 1986;320:454-456.
21. Lob HE, Vinh A, Li L, et al. Role of vascular extracellular superoxide dismutase in hypertension. Hypertension. 2011;58:232-239.
22. Faraci FM, Didion SP. Vascular protection: Superoxide dismutase isoforms in the vessel wall. Arterioscler Thromb Vasc Biol. 2004;24:1367- 1373.
23. Foresman EL, Miller FJ Jr. Extracellular but not cytosolic superoxide dismutase protects against oxidant-mediated endothelial dysfunction. Redox Biol. 2013;1:292-296.
24. Jung O, Marklund SL, Geiger H, et al. Extracellular superoxide dismutase is a major determinant of nitric oxide bioavailability: in vivo and ex vivo evidence from ecSOD-deficient mice. Circ Res. 2003;93:622-629.
25. Adachi T, Inoue M, Hara H, et al. Relationship of plasma extracellularsuperoxide dismutase level with insulin resistance in type 2 diabetic patients. J Endocrinol. 2004;181:413-417.
26. Prasad A, Stone GW, Holmes DR, et al. Reperfusion injury, microvascular dysfunction, and cardioprotection: The "dark side" of reperfusion. Circulation. 2009;120:2105-2112.
27. Wang Y, Yu L, Cui N, et al. Differential sensitivities of the vascular K (ATP) channel to various PPAR activators. Biochem Pharmacol. 2013; 85:1495-1503.
28. Radomski MW, Palmer RM, Moncada S. The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol. 1987;92:639-646.
29. Naka KK, Papathanassiou K, Bechlioulis A, et al. Effects of pioglitazone and metformin on vascular endothelial function in patients with type 2 diabetes treated with sulfonylureas. Diab Vasc Dis Res. 2012;9: 52-58.
30. Derosa G, Mereu R, D'Angelo A, et al. Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin. J Clin Pharm Ther. 2010;35: 565-579.
31. Fujisawa K, Nishikawa T, Kukidome D, et al. TZDs reduce mitochondrial ROS production and enhance mitochondrial biogenesis. Biochem Biophys Res Commun. 2009;379:43-48.
32. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
33. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-2559.
34. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358:2560-2572.
35. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360: 129-139.
36. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369: 1327-1335.
37. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317-1326.
38. Elliott WC, Houghton DC, Gilbert DN, et al. Gentamicin nephrotoxicity. I. Degree and permanence of acquired insensitivity. J Lab Clin Med. 1982;100:501-512.